{"id":30158,"date":"2025-03-24T16:50:57","date_gmt":"2025-03-24T08:50:57","guid":{"rendered":"https:\/\/flcube.com\/?p=30158"},"modified":"2025-03-24T16:50:58","modified_gmt":"2025-03-24T08:50:58","slug":"harbour-biomed-partners-with-astrazeneca-on-multi-specific-antibody-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30158","title":{"rendered":"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development"},"content":{"rendered":"\n

China-based Harbour BioMed (HKG: 2142<\/a>) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN<\/a>) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed’s proprietary Harbour Mice fully human antibody technology platform across various therapeutic areas, alongside a USD 105 million equity investment in Harbour Bio.<\/p>\n\n\n\n

Collaboration Details<\/strong>
Under the agreement, AstraZeneca will obtain the option to license two preclinical immunology programs and will nominate additional targets for Harbour BioMed to discover next-generation multi-specific antibodies. AstraZeneca will have the option to license these programs for advancement into clinical development, with an initial focus on ongoing research programs and potential for expansion into additional areas. As part of the collaboration, an innovation center will be jointly established in Beijing to facilitate research and development efforts.<\/p>\n\n\n\n

Financial Terms<\/strong>
Financially, AstraZeneca will provide an upfront payment, near-term milestone payments, and option exercise fees for additional programs, totaling USD 175 million. The deal also includes up to USD 4.4 billion in additional development and commercial milestone payments, along with tiered royalties on future net sales. Furthermore, AstraZeneca will acquire 9.15% newly issued shares of Harbour BioMed, reflecting a significant commitment to the partnership and the potential of Harbour BioMed’s technology platform.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca…<\/p>\n","protected":false},"author":1,"featured_media":30159,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[130,30,20,190,916,871],"class_list":["post-30158","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-astrazeneca","tag-biotech","tag-finance","tag-harbour-biomed","tag-hkg-2142","tag-nasdaq-azn"],"yoast_head":"\nHarbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed's proprietary Harbour Mice fully human antibody technology platform across various therapeutic areas, alongside a USD 105 million equity investment in Harbour Bio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30158\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development\" \/>\n<meta property=\"og:description\" content=\"China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed's proprietary Harbour Mice fully human antibody technology platform across various therapeutic areas, alongside a USD 105 million equity investment in Harbour Bio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30158\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-24T08:50:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-24T08:50:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2402-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30158#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30158\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development\",\"datePublished\":\"2025-03-24T08:50:57+00:00\",\"dateModified\":\"2025-03-24T08:50:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30158\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30158#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2402-png.webp\",\"keywords\":[\"AstraZeneca\",\"Biotech\",\"Finance\",\"Harbour BioMed\",\"HKG: 2142\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30158#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30158\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30158\",\"name\":\"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30158#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30158#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2402-png.webp\",\"datePublished\":\"2025-03-24T08:50:57+00:00\",\"dateModified\":\"2025-03-24T08:50:58+00:00\",\"description\":\"China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed's proprietary Harbour Mice fully human antibody technology platform across various therapeutic areas, alongside a USD 105 million equity investment in Harbour Bio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30158#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30158\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30158#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2402-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2402-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30158#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development - Insight, China's Pharmaceutical Industry","description":"China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed's proprietary Harbour Mice fully human antibody technology platform across various therapeutic areas, alongside a USD 105 million equity investment in Harbour Bio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30158","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development","og_description":"China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed's proprietary Harbour Mice fully human antibody technology platform across various therapeutic areas, alongside a USD 105 million equity investment in Harbour Bio.","og_url":"https:\/\/flcube.com\/?p=30158","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-24T08:50:57+00:00","article_modified_time":"2025-03-24T08:50:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2402-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30158#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30158"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development","datePublished":"2025-03-24T08:50:57+00:00","dateModified":"2025-03-24T08:50:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30158"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30158#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2402-png.webp","keywords":["AstraZeneca","Biotech","Finance","Harbour BioMed","HKG: 2142","NASDAQ: AZN"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30158#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30158","url":"https:\/\/flcube.com\/?p=30158","name":"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30158#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30158#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2402-png.webp","datePublished":"2025-03-24T08:50:57+00:00","dateModified":"2025-03-24T08:50:58+00:00","description":"China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed's proprietary Harbour Mice fully human antibody technology platform across various therapeutic areas, alongside a USD 105 million equity investment in Harbour Bio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30158#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30158"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30158#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2402-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2402-png.webp","width":1080,"height":608,"caption":"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30158#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2402-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30158"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30158\/revisions"}],"predecessor-version":[{"id":30160,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30158\/revisions\/30160"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30159"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}